Research News

Learn more about the Evolution of H3N2 Influenza Virus in an important study.  Click here to learn more.

Technology

dreamstime_1877959 dreamstime_5690275

A striking disparity exists between the small number of diseases currently prevented by available vaccines and the many infectious diseases for which no vaccine is available. Given approximately 200 years of “modern” vaccine development, there are currently only 26 human vaccines licensed for use in the United States. In general many of these vaccines are whole killed or attenuated preparations with a smaller number being subunit in nature.


There are many other infectious diseases to which the same traditional vaccine approaches fail to generate protective vaccines. Major obstacles in vaccine design are ineffective immune responses and antigenic variation. While there are a multitude of research and development activities directed at improving the magnitude of vaccine immune responses, i.e. novel vectors, adjuvants, antigen-presentation strategies, expression systems, and cytokines, vaccine solutions have not yet addressed the problem of genetic instability and antigenic variation of the pathogen, which we believe stands as the single most important obstacle in vaccine design today. BMI’s Immune Dampening and Refocusing Technology is a method that defeats this problem of antigenic variation or “Deceptive Imprinting.”

Search Site

Virus Developments

BMI is developing an AIDS vaccine and applying its Immune Dampening and Refocusing Technology to the outer HIV envelope glycoprotein gp120/gp41, which is the main mediator of viral fusion and entry with host receptors CD4 and chemokine receptors CCR5 and/or CXCR4.

The Latest Technology

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Research & Development

dreamstime_13272506Biological Mimetics, Inc. research and development includes veterinary applications such as:
Foot and Mouth Disease Virus , Infectious Pancreatic Necrosis Virus,
and
Porcine Reproductive and Respiratory Syndrome Virus.

Company News

blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems
blk triangleMay 2008: BMI is awarded a subcontract for HIV vaccine development through the Henry M Jackson Institute for the Advancement of Military Medicine.
blk triangleJuly 2007: BMI is awarded a subcontract from DARPA through Rice University to study the evolution of pathogens
blk triangleJune 2007: BMI is awarded a subcontract from DARPA through VaxDesign (Orlando, Florida) to study immunogenicity of influenza